Should I Buy FOLD? FOLD 2026 Analysis

Should You Buy Amicus Therapeutics Inc (FOLD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

14.300

1 Day change

0.14%

52 Week Range

14.380

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: price action is stalled at/just below the pivot (~14.29) with slightly bearish momentum (MACD below 0) and no proprietary buy signals.
Downside risk is elevated near-term due to heavy insider selling (+110.68% last month) and a negative headline (law firm investigation) ahead of earnings (QDEC 2025 on 2026-02-27 pre-market).
If you’re impatient and want immediate upside, this setup doesn’t offer a strong edge; risk/reward is not attractive until the stock shows a clean reclaim of resistance (~14.31+) with improving momentum.

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend/Momentum: MACD histogram -0.14 (below zero) but contracting → bearish momentum is easing, yet not flipped bullish.
RSI(6)=49.1 → neutral; no oversold bounce signal.
Moving averages: converging → consolidation/chop; not a clear trend.
Key levels: price ~14.265 sitting on S1=14.264 (near-term support). Resistance overhead at Pivot=14.287 and R1=14.31; a failure to reclaim 14.29–14.31 keeps the tape range-bound to weak.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning: Put/Call OI ratio 0.79 (more call OI than put OI) → mildly bullish positioning.
Activity: reported option volume is 0 today → sentiment read is limited (OI exists, but no fresh flow).
Volatility: IV30 ~69.1 vs HV ~76.5; IV percentile ~53 → options are mid-range priced, not screaming fear/greed.

Technical Summary

Sell

Buy

Positive Catalysts

- Upcoming earnings catalyst: QDEC 2025 earnings on 2026-02-27 (pre-market) could re-rate shares if guidance/launch metrics surprise.
- Street upside exists: Citi Buy PT $17 and JPM Overweight PT $19 imply meaningful upside if execution stays strong.
- Prior strategic/takeover interest was noted in analyst commentary (even if now considered less likely).

Neutral/Negative Catalysts

- Insider selling is rising sharply (+110.68% last month) → negative signal for near-term conviction.
- Jefferies downgrade to Hold with PT $14.50 (near current price) and commentary that further takeover bids are unlikely.
- Legal headline: Halper Sadeh LLC investigating potential securities law issues (often a sentiment overhang regardless of merit).
- Event risk into earnings: if EPS/revenue/guidance disappoints, current support near ~14.25–14.26 can break quickly.

Financial Performance

Latest reported quarter: 2025/Q3.
Revenue: $169.1M, +19.46% YoY → solid top-line growth trend.
Profitability: Net income $17.3M, down -357.19% YoY; EPS $0.06, down -400% YoY → earnings quality/consistency is a concern despite revenue growth.
Gross margin: 87.38%, down ~1.91% YoY → still very high, but slightly compressing.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent changes: JPMorgan reiterated Overweight and raised PT to $19 (2025-11-06); Citi initiated Buy with $17 (2025-12-17); Jefferies downgraded to Hold and cut PT to $14.50 (2026-01-22) citing low odds of additional takeover bids.
Wall Street pros: strong rare-disease commercial story and long-run sales potential (bull case).
Wall Street cons: reduced M&A optionality and nearer-term upside capped around current price per Jefferies; sentiment also hurt by insider selling.
Influential/political trading: No recent congress trading data available; no politician activity indicated in provided data.

10 Analyst Rating

Wall Street analysts forecast FOLD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for FOLD is 14.25 USD with a low forecast of 11 USD and a high forecast of 19 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

7 Hold

0 Sell

Moderate Buy

Current: 14.280

Low

Averages

14.25

High

Current: 14.280

Low

Averages

14.25

High

Jefferies

Buy

Hold

downgrade

$16

AI Analysis

2026-01-22

Reason

Jefferies

Price Target

$16

AI Analysis

2026-01-22

downgrade

Buy

Hold

Reason

Jefferies downgraded Amicus to Hold from Buy with a price target of $14.50, down from $16. Proxy documents show the company did receive extensive pharma takeover interest beyond BioMarin, the analyst tells investors in a research note. As such, Jefferies does not expect additional takeover bids for Amicus.

Citi

Samantha Semenkow

Buy

initiated

$17

2025-12-17

Reason

Citi

Samantha Semenkow

Price Target

$17

2025-12-17

initiated

Buy

Reason

Citi analyst Samantha Semenkow initiated coverage of Amicus with a Buy rating and $17 price target. The company is focused on commercializing rare disease therapies, the analyst tells investors in a research note. The firm believes Galafold and PomOp are positioned for combined sales of over $1B in 2028.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for FOLD

Unlock Now

FOLD Should I Buy

FOLD Should I Buy

Should You Buy Amicus Therapeutics Inc (FOLD) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch